The three drugs are glucagon-like peptide 1 receptor agonists, a drug class that has seen high demand after popularity trickled from celebrities to the masses on social media clamoring for weight-loss results. In October, #Ozempicweightloss saw more than 85 million views and #ozempic has been seen 227 million times on TikTok. The drug is approved only for Type 2 diabetes, but physicians can prescribe the medication for off-label use, such as weight management.
Since its approval in late 2017, Ozempic accounts for 65.4 percent of the GLP-1 market, according to Trilliant Health.
Between the first quarter of 2020 and the end of 2022, prescription volumes for GLP-1 medications increased 300 percent, according to the analysis; that figure exceeds the rate of diabetes prevalence. A slight majority, or 53.8 percent, of patients with GLP-1 prescriptions have a history of diabetes, the report found.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
